FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
Clinical Summary:
- The FDA approved a rituximab biosimilar referencing Rituxan for the same approved oncology and immunology indications based on a comprehensive biosimilar development program that included analytical, nonclinical, pharmacokinetic, and clinical studies.
- The totality of evidence demonstrated the biosimilar is highly similar to Rituxan, with no clinically meaningful differences in safety, purity, or potency, meeting FDA requirements for biosimilar approval.
- The approval expands access to a CD20-directed biologic across multiple hematologic malignancies and autoimmune diseases, adding another treatment option to the growing U.S. biosimilars landscape.
The FDA has approved a rituximab biosimilar referencing rituximab (Rituxan) for the treatment of multiple hematologic malignancies and autoimmune diseases, expanding the availability of CD20-directed biologic therapy in the United States.
The approval was supported by a comprehensive biosimilar development program employing the FDA's totality-of-the-evidence approach. Analytical, nonclinical, pharmacokinetic, and clinical data demonstrated that the biosimilar is highly similar to the reference product, with no clinically meaningful differences in safety, purity, or potency, consistent with FDA requirements for biosimilar approval.
Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on B lymphocytes, leading to B-cell depletion through multiple immune-mediated mechanisms. In the United States, rituximab is approved for adults with several B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Under an exclusive commercialization agreement, Fresenius Kabi will commercialize the biosimilar in the United States. The product was developed, manufactured, and submitted for FDA review by Dr. Reddy's Laboratories.
"FDA approval of rituximab biosimilar represents an important milestone for Fresenius Kabi, further strengthening our US biosimilars footprint with a well-established molecule that strategically complements our oncology and immunology portfolios," stated Sang-Jin Pak, MD, President of Biopharma at Fresenius Kabi. "This reinforces our commitment to expanding patient access to high-quality, affordable biologic medicines in the US market."
Rituximab products carry a boxed warning for fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. Additional warnings include the risk of serious infections and other clinically significant adverse reactions.
The approval adds to the expanding biosimilar landscape in oncology and immunology and is intended to increase patient access to rituximab therapy across its approved indications.
Source:
Businesswire. Fresenius announces FDA approval of rituximab biosimilar for the U.S. market. Accessed on August 4, 2026. https://www.businesswire.com/news/home/20260803326443/en/Fresenius-Announces-FDA-Approval-of-Rituximab-Biosimilar-for-the-U.S.-Market
